AU2022246101A1 - Pharmaceutical compositions comprising zolmitriptan - Google Patents

Pharmaceutical compositions comprising zolmitriptan Download PDF

Info

Publication number
AU2022246101A1
AU2022246101A1 AU2022246101A AU2022246101A AU2022246101A1 AU 2022246101 A1 AU2022246101 A1 AU 2022246101A1 AU 2022246101 A AU2022246101 A AU 2022246101A AU 2022246101 A AU2022246101 A AU 2022246101A AU 2022246101 A1 AU2022246101 A1 AU 2022246101A1
Authority
AU
Australia
Prior art keywords
composition
zolmitriptan
points
hours
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022246101A
Other languages
English (en)
Inventor
James Lillie
Michael Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MapLight Therapeutics Inc
Original Assignee
MapLight Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MapLight Therapeutics Inc filed Critical MapLight Therapeutics Inc
Publication of AU2022246101A1 publication Critical patent/AU2022246101A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022246101A 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan Pending AU2022246101A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163165938P 2021-03-25 2021-03-25
US63/165,938 2021-03-25
US202263306377P 2022-02-03 2022-02-03
US63/306,377 2022-02-03
PCT/US2022/021738 WO2022204399A1 (en) 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan

Publications (1)

Publication Number Publication Date
AU2022246101A1 true AU2022246101A1 (en) 2023-10-12

Family

ID=83397893

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022246101A Pending AU2022246101A1 (en) 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan

Country Status (10)

Country Link
US (1) US20240189240A1 (https=)
EP (1) EP4313037A4 (https=)
JP (1) JP2024512069A (https=)
KR (1) KR20240004330A (https=)
AU (1) AU2022246101A1 (https=)
BR (1) BR112023019407A2 (https=)
CA (1) CA3213383A1 (https=)
IL (1) IL307194A (https=)
MX (1) MX2023011240A (https=)
WO (1) WO2022204399A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017983B (zh) * 2023-10-09 2023-12-22 中山大学 曲普坦类药物在制备抗感染药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
US20100179202A1 (en) * 2009-01-14 2010-07-15 Ajanta Pharma Limited. Orally disintegrating composition of zolmitriptan
CN104411301B (zh) * 2012-04-18 2018-02-06 康特拉医药公司 适于改善运动障碍治疗的口服药物配方
KR20160117596A (ko) * 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
HUE059559T2 (hu) * 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
ES3056138T3 (en) * 2019-10-23 2026-02-18 Maplight Therapeutics Inc Methods of treating the symptoms of autism spectrum disorder

Also Published As

Publication number Publication date
BR112023019407A2 (pt) 2023-11-28
KR20240004330A (ko) 2024-01-11
MX2023011240A (es) 2024-01-12
JP2024512069A (ja) 2024-03-18
WO2022204399A1 (en) 2022-09-29
EP4313037A4 (en) 2025-02-26
CA3213383A1 (en) 2022-09-29
US20240189240A1 (en) 2024-06-13
IL307194A (en) 2023-11-01
EP4313037A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
JP6233985B2 (ja) 不眠症の治療用薬剤の遅動型剤形
US7915247B1 (en) Methods of use of fenofibric acid
RU2298402C2 (ru) Твердая лекарственная форма тербинафина для перорального введения
KR100882707B1 (ko) 라모트리진을 포함하는 서방형 제제
US20120039954A1 (en) Method of treating insomnia
US10617651B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
MX2013010920A (es) Metodos y composiciones para el tratamiento de transtorno por deficit de atencion.
EA038198B1 (ru) Способы и композиции, в частности, для лечения синдрома дефицита внимания
US9283214B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US20150313849A1 (en) Methods of Treatment of Attention Deficit Hyperactivity Disorder
KR20230008913A (ko) 알펠리십을 포함하는 제약 조성물
US11696895B2 (en) Fine particle coating (drug-containing hollow particle and method for manufacturing same)
US20240189240A1 (en) Pharmaceutical compositions comprising zolmitriptan
US20260027063A1 (en) Compositions for Treatment of Attention Deficit Hyperactivity Disorder
EP2298290A1 (en) Controlled release composition comprising levetiracetam
US10905652B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
CN117750957A (zh) 包含佐米曲坦的药物组合物
CA2708832A1 (en) O-desmethyl-venlafaxine for treating major depressive disorder
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
US20140322313A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist
KR20230129433A (ko) 피리도스티그민을 포함하는 연장된 방출 조성물
HK40097882A (zh) 包含吡斯的明的延长释放组合物
Patel Formulation and evaluation of ranolazine sustained release tablets by hot melt coating technique
AMITRIPTYLINE in partial fulfilment of the requirements for the award of degree of MASTER OF PHARMACY IN PHARMACEUTICS